FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years) w/ active polyarticular juvenile idiopathic arthritis (pJIA) & psoriatic arthritis (PsA), after inadequate resp/intolerance to TNFi. Also available as oral solution. https://t.co/lGvIHb8wfZ https://t.co/8BiTnTNJzO
Links:
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older…
https://buff.ly/4bRlPL6
Jun-05-2024
